More Insights
Healthcare Delivery and Payers Pharmaceuticals and Medical DevicesChallenges
- Healthcare Delivery and Payers
- Pharmaceuticals and Medical Devices
Building Value Considerations into R&D
eyeforpharma
With spiraling cost inflation and lagging quality indicators driving a transition to a value-based system, public and private payers are using sophisticated tools, including health technology assessment (HTA), to evaluate the benefits of the products they buy. In this environment, companies must demonstrate both clinical efficacy and differentiated economic value…
Barriers to Realizing Biosimilars’ Potential
PM360
For quite some time, providers, public and private payers, policy-makers, pharmacy benefit managers and patients have hoped the arrival of biosimilars would usher in a new era of competitive drug prices. However, as the U.S. market prepares to welcome its second biosimilar, Celltrion’s Inflectra, the future of biosimilars in this…
Managing Portfolios to Deliver Economic and Clinical Value
Applied Clinical Trials
Economic and clinical value has become the basis for both differentiation and maintaining premium pricing, and the importance of the economic and clinical value case is likely only to increase. This trend is truly global in scope, applies to multiple key stakeholder groups (payers, physicians, and patients), and is particularly…
Market Segmentation in the New Healthcare Landscape
eyeforpharma
Increasingly, pharmaceutical companies are being asked – if not required – to demonstrate that their products deliver economic and clinical value to a wide range of stakeholders, including payers, providers, pharmacy benefit managers (PBMs), and patients. In the past, regulatory approval alone was sufficient to successfully bring a new product…
Patients as Partners? The Role for “Patient Centricity” in the New Healthcare Landscape
eyeforpharma
The healthcare system — in the U.S. and globally — is responding to the need to reduce costs and improve outcomes. The foremost implication for manufacturers of pharmaceuticals, devices, and diagnostics is a drive to demonstrate the economic and clinical value of their products to all stakeholders… including patients. This…
